Literature DB >> 19423505

Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker.

Mariaelena Pierobon1, Valerie Calvert, Claudio Belluco, Enrico Garaci, Jianghong Deng, Mario Lise, Donato Nitti, Enzo Mammano, Francesco De Marchi, Lance Liotta, Emanuel Petricoin.   

Abstract

The identification of prognostic determinants of colorectal cancer (CRC), including prediction of occult metastasis, is of urgent consideration, based on the tremendous differences in outcome and survival between patients who present with metastasis or develop metastasis versus those patients with organ-confined or nonrecurrent disease. Currently, a great deal of attention has been focused on using gene expression profiles of tumor specimens as a launch point for prognostic biomarker discovery. In our study, we chose to focus on functional protein-based pathway biomarkers as a new information archive because it is these proteins that form the functional signaling networks that control cell growth, motility, apoptosis, survival, and differentiation. We used reverse-phase protein microarray analysis of laser capture microdissected CRC tumor specimens to profile broad cell signaling pathways from patients who presented with liver metastasis versus patients who remained recurrence free after follow-up. Our results indicate that members of the EGFR and COX2 signaling pathways appear differentially activated in the primary tumors of patients with synchronous metastatic disease. If validated in larger study sets, this pathway defect might be useful as a prognostic clinical tool as well as a guide to potential therapeutic intervention strategies that target occult disease and/or preventative measure.

Entities:  

Year:  2009        PMID: 19423505     DOI: 10.3816/CCC.2009.n.018

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  21 in total

1.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

2.  Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Authors:  Mariaelena Pierobon; Corinne Ramos; Shukmei Wong; K Alex Hodge; Jessica Aldrich; Sara Byron; Stephen P Anthony; Nicholas J Robert; Donald W Northfelt; Mohammad Jahanzeb; Linda Vocila; Julia Wulfkuhle; Guido Gambara; Rosa I Gallagher; Bryant Dunetz; Nicholas Hoke; Ting Dong; David W Craig; Massimo Cristofanilli; Brian Leyland-Jones; Lance A Liotta; Joyce A O'Shaughnessy; John D Carpten; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

3.  Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

Authors:  Giuseppina Improta; Angela Zupa; Helen Fillmore; Jianghong Deng; Michele Aieta; Pellegrino Musto; Lance A Liotta; William Broaddus; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  J Proteome Res       Date:  2011-05-27       Impact factor: 4.466

4.  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Authors:  Alessandra Silvestri; Valerie Calvert; Claudio Belluco; Michael Lipsky; Ruggero De Maria; Jianghong Deng; Alfonso Colombatti; Francesco De Marchi; Donato Nitti; Enzo Mammano; Lance Liotta; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Clin Exp Metastasis       Date:  2012-09-29       Impact factor: 5.150

Review 5.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.

Authors:  Henry Rodriguez; Robert Rivers; Christopher Kinsinger; Mehdi Mesri; Tara Hiltke; Amir Rahbar; Emily Boja
Journal:  Proteomics Clin Appl       Date:  2010-11-22       Impact factor: 3.494

Review 7.  Restructuring proteomics through verification.

Authors:  Emily Boja; Robert Rivers; Christopher Kinsinger; Mehdi Mesri; Tara Hiltke; Amir Rahbar; Henry Rodriguez
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

8.  Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Authors:  Benedetta Accordi; Virginia Espina; Marco Giordan; Amy VanMeter; Gloria Milani; Luisa Galla; Maria Ruzzene; Manuela Sciro; Luca Trentin; Ruggero De Maria; Geertruy te Kronnie; Emanuel Petricoin; Lance Liotta; Giuseppe Basso
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Authors:  Angela Zupa; Giuseppina Improta; Alessandra Silvestri; Elisa Pin; Jianghong Deng; Michele Aieta; Pellegrino Musto; Donato Nitti; Enzo Mammano; Lance Liotta; Claudio Belluco; Julia Wulfkuhle; Emanuel Petricoin
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.